Substandard edible oil found in Nandurbar: Minister warns of action
The matter was raised by MLA Aamshya Padvi, with follow-up questions from members Sameer Kunawar and Hiraman Khoskar.
Responding to the question in the Lower House, Minister Zirwal said that on March 10, the FDA inspected the Gopal Provision Store in Akkalkuwa.
During the inspection, samples of Mahika brand refined soybean oil and Kamla brand groundnut oil were collected for testing. Preliminary reports indicated that the samples were substandard as per food safety norms.
Following an appeal by the vendor, the samples were sent for further analysis to the Central Food Technological Research Institute (CFTRI) in Mysuru.
Zirwal added that in the financial year 2024–25, 12 edible oil samples were tested in the district, of which five were found to be of inferior quality.
'Out of these, legal action has been initiated in two cases under the Food Safety and Standards Act, 2006. The remaining three are awaiting final reports from referral laboratories,' the minister said. Zirwal told the House that strict measures will be taken against those found violating food safety norms.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
18 hours ago
- Hans India
New weekly injection to offer steady Parkinson's medication, cut need for daily pills
A team of scientists in Australia, led by those of Indian origin, has developed a new once-a-week injectable drug that could transform the lives of more than eight million people living with Parkinson's disease, potentially replacing the need for multiple daily tablets. Frequent dosing is a burden, especially for elderly patients or those with swallowing difficulties, leading to inconsistent medication levels, more side effects, and reduced effectiveness. To address this, the team from the University of South Australia (UniSA) developed a long-acting injectable formulation that delivers a steady dose of levodopa and carbidopa -- two key medications for Parkinson's -- over an entire week. The biodegradable formulation is injected under the skin or into muscle tissue, where it gradually releases the medication over seven days, noted the researchers in the paper published in the journal Drug Delivery and Translational Research. The newly developed injectable could significantly improve treatment outcomes and patient adherence, said lead researcher Professor Sanjay Garg, from UniSA's Center for Pharmaceutical Innovation. "Our goal was to create a formulation that simplifies treatment, improves patient compliance, and maintains consistent therapeutic levels of medication. This weekly injection could be a game-changer for Parkinson's care," Garg said. "Levodopa is the gold-standard therapy for Parkinson's, but its short lifespan means it must be taken several times a day." The injectable gel combines a US FDA-approved biodegradable polymer, PLGA, with Eudragit L-100, a pH-sensitive polymer, to achieve a controlled and sustained drug release. The team noted that the release of both levodopa and carbidopa steadily over a week could help maintain consistent plasma levels and reduce the risks associated with fluctuating drug concentrations. Extensive lab tests confirmed the system's effectiveness and safety. More than 90 per cent of the levodopa dose and more than 81 per cent of the carbidopa dose were released over seven days. Notably, the implant degraded by over 80 per cent within a week and showed no significant toxicity in cell viability tests. In addition, the formulation can be easily administered through a fine 22-gauge needle, minimising discomfort and eliminating the need for surgical implantation. Garg said the technology could also be adapted for other chronic conditions such as cancer, diabetes, neurodegenerative disorders, pain management, and chronic infections that require long-term drug delivery.
Mint
a day ago
- Mint
FDA Offers to Trade Faster Drug Reviews for Lower US Prices
Food and Drug Administration Commissioner Marty Makary said his agency may fast-track new drugs from pharmaceutical companies that 'equalize' the cost of their medicines between the US and other countries, an unusual proposition from the regulator that's long avoided contentious pricing debates. The comments, made in an interview on Bloomberg Television's Wall Street Week with David Westin, offer insight into an idea floated to help the administration achieve one of President Donald Trump's main health-care goals: ensuring foreign countries aren't getting a better deal on drugs. Trump demanded that Americans get similar or lower prices as consumers in other countries in an executive order signed in May. Price adjustments may give companies another way to obtain 'national priority vouchers,' the reward that comes as part of a new program the FDA announced last month that would slash review times for companies it says are backing national interests. Makary didn't offer details about how drugmakers would have to adjust their prices to qualify for a voucher. 'We can issue a national priority review voucher for companies that are promising to equalize the price' between the US and what other foreign countries pay, Makary said. 'We want to incentivize good behavior in the marketplace, and these priority vouchers are worth a lot of money.' The new vouchers would cut review times to one to two months, down from an average of about 10 months to one year now, the agency said. In the interview, Makary said the program could be used as a tool to even out drug prices with those currently charged in places like Europe. The Department of Health and Human Services has asked drugmakers to price therapies that don't have generic competition at the lowest level offered to any member country in the Organization for Economic Cooperation and Development that has an economy at least 60% of the size of the US on a per capita basis. The FDA typically has avoided inserting itself into the murky world of drug pricing in the US. Explicitly trading faster reviews for price changes on existing treatments would be abnormal for the agency, which doesn't have authority 'to investigate or control the prices charged for marketed drugs.' It's also unclear how much of an impact the vouchers would have. Makary touted the value of pediatric priority review vouchers offered under a different program, which is currently coming to an end. He noted that some have sold for more than $100 million in a secondary market, which was legal. The new national priority vouchers can't be sold. Drugmakers also have limited control over what patients ultimately pay in the US, where a complex system of insurance companies and drug benefit managers typically operates in the space between where a patient is given a prescription and where they get their medicine from a pharmacy. Still, the approach could offer a financial incentive for drugmakers to lower drug prices. When Trump pursued equalizing costs in the US with those abroad during his first term, he exclusively used a more punitive approach, issuing regulations that would have reduced what Medicare, the health insurance program for the elderly and disabled, pays for medications administered in physicians' offices. In the initial announcement of the voucher program, FDA said they could be offered to return drug manufacturing to the US, address health crises or unmet public health needs, or provide innovative cures. The interview will air Friday at 6 p.m. in New York.
Hans India
2 days ago
- Hans India
Minister Ponguleti Inaugurates Derma 360's World-Class Aesthetic Clinic in Hyderabad
Hyderabad: Derma 360 unveiled its fourth state-of-the-art aesthetic clinic in Kavuri Hills, inaugurated by Minister Ponguleti Srinivasa Reddy. Backed by a global team led by Dr. Bala K. Ravi, the clinic offers advanced surgical and non-surgical solutions, including cosmetic surgery, laser therapies, and holistic wellness programs. With over 75 years of combined expertise, Derma 360 promises top-tier, FDA-approved treatments in a patient-centric environment. The minister expressed hopes for it to rank among Hyderabad's top 5 clinics. This launch marks a new benchmark in aesthetic excellence for the city.
